Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03153527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Taper Or Abrupt Steroid Stop: TOASSTtrial

Study acronym: TOASST
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description revised
    • Site contacts updated at 1 of 16 sites
    v16
  2. Enrollment target: 573 to 530
    • Study sites: 15 to 16
    • Primary and study completion dates: Dec 2026 to Jun 2027
    • Collaborators: 3 to 4
    v15
  3. Primary and study completion dates: Dec 2024 to Dec 2026v14
  4. Re-verified, no change to tracked fieldsv13
  5. Study sites: 14 to 15v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary and study completion dates: Dec 2020 to Dec 2024
    • Study sites: 10 to 14
    v11
  2. Re-verified, no change to tracked fieldsv10
  3. Study sites revised (10)
    • Collaborators: 1 to 3
    v9
  4. Site contacts updated at 1 of 10 sitesv8
  5. Study sites: 9 to 10v7
  6. Site details revised at 1 of 9 sitesv6
  7. Study sites: 8 to 9v5
  8. Eligibility criteria revisedv4
  9. Eligibility criteria shortened, about 7 words
    • Study description expanded, about 15 words
    v3
  10. Start date changed from estimate of May 2017 to May 31, 2017
    • Study description shortened, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.
Trial Details
NCT Number NCT03153527
Lead Sponsor University Hospital, Basel, Switzerland
Collaborators: Kantonsspital Baselland Bruderholz, Swiss National Science Foundation, HEMMI Stiftung Switzerland, Gebauer Stiftung Zurich
Conditions
(from sponsor)		 Inflammatory Disorder, Autoimmune
Enrollment 530 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov